Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

The role of innovation in shaping the future of health communications

The future is full of potential – if we’re brave enough to experiment

- PMLiVE

Pfizer and Triana enter molecular glue degrader partnership worth over $1.5bn

The companies will aim to discover new drugs for cancer and other severe diseases

- PMLiVE

AstraZeneca’s Voydeya recommended by NICE to treat rare blood disorder PNH

The drug has been recommended for use alongside the company’s C5 inhibitors

- PMLiVE

ESMO 2024 – how pharma is breathing life into cancer comms

Susanne Bobadilla from VML Health, joined by a team of 15 medical, digital strategists and client engagement experts from across the company, looks at the top trends coming out of...

Adopting a Growth Mindset – Building Company Culture Virtually

Transform challenges into opportunities with our new video series on creating vibrant company culture remotely. Learn how adopting a growth mindset can enhance your leadership and foster a thriving remote...

Impetus Digital

- PMLiVE

Eli Lilly’s Alzheimer’s drug Kisunla approved by MHRA but not recommended by NICE

The health technology assessment agency said that more evidence is needed on the clinical and cost-effectiveness of the drug

- PMLiVE

Ipsen’s Iqirvo recommended by NICE to treat rare liver disease primary biliary cholangitis

The disease affects approximately 25,000 people in the UK, the majority of whom are women

- PMLiVE

Unlocking potential: key life sciences priorities for the Autumn Budget

By Ahmed Moussa

- PMLiVE

Investment and impact: navigating the complexities of a European launch

By Hristo Deyanov

- PMLiVE

What is health literacy, and why should it matter to us?

Dr Alexandra Loveday explores the concept of health literacy and why it matters so much when crafting comms and medical education materials aimed at patients.

Mednet

- PMLiVE

Merck’s Keytruda recommended by NICE to reduce risk of lung cancer recurrence

More than 5,000 patients in England are expected to be eligible for the anti-PD-1 therapy

- PMLiVE

AstraZeneca/Ionis’ Wainzua receives positive CHMP opinion to treat rare disease ATTRv-PN

The drug can be self-administered via an auto-injector and is designed to lower the production of TTR protein at its source

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links